Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes

NCT02061085 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT02061085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02061085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
December 31, 2015
Enrollment
53 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm, metastasis